Related Experiment Video
Updated: Aug 11, 2026
14:57
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Antiepileptic drug therapy in the elderly
1Department of Neurology, University of Texas Medical School, Houston 77030, USA.
Pharmacology & Therapeutics
|May 21, 1998
Summary
As populations age, epilepsy incidence rises in older adults. Standard antiepileptic drugs pose risks due to age-related physiological changes, necessitating safer alternatives for elderly epilepsy patients.
Area of Science:
- Gerontology
- Neurology
- Clinical Pharmacology
Background:
- Global populations are aging, leading to a higher incidence of epilepsy in the elderly.
- Age-related physiological changes affect drug metabolism and excretion in older adults.
- Standard antiepileptic drugs (AEDs) can cause dose-related adverse effects in elderly patients.
Purpose of the Study:
- To highlight the importance of understanding antiepileptic drug use in aging populations.
- To identify challenges associated with standard AEDs in elderly patients.
- To explore potential benefits of newer antiepileptic compounds for geriatric care.
Main Methods:
- Review of demographic trends in aging populations and epilepsy incidence.
- Analysis of physiological changes in healthy elderly individuals affecting drug pharmacokinetics.
- Evaluation of adverse effect profiles of standard AEDs in older adults.
Main Results:
- Elderly patients exhibit altered renal blood flow, hepatic function, and body composition.
- These changes increase vulnerability to dose-related adverse effects from conventional AEDs.
- Newly developed AEDs may offer improved safety profiles for the elderly.
Conclusions:
- Age-related physiological alterations necessitate careful consideration of AED selection in older adults.
- Standard AEDs may not be optimal for elderly patients due to increased adverse effect risks.
- Novel antiepileptic agents with reduced enzyme induction and non-renal excretion pathways show promise for safer geriatric epilepsy management.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...